TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03264105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional resin-based flowable composite
Description: retention rate evaluation of conventional resin-based flowable composite
Study: NCT02093429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: INCB047986 will be supplied as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: INCB047986 will be supplied as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: INCB047986 will be supplied as tablets.
Study: NCT01488539

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
Study: NCT03653897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader
Study: NCT02426255

Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
Study: NCT00672087

Intervention type: GENETIC
Intervention: Genomic and proteomic biomarker discovery
Description: Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

Intervention type: GENETIC
Intervention: Genomic and proteomic biomarker discovery
Description: Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

Intervention type: GENETIC
Intervention: Genomic and proteomic biomarker discovery
Description: Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
Study: NCT02370537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova® (omega-3 carboxylic acids)
Description: 4 g (administered orally as 4 x 1 g capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova® (omega-3 carboxylic acids)
Description: 4 g (administered orally as 4 x 1 g capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor® (omega-3-acid ethyl esters)
Description: 4 g (administered orally as 4 x 1 g capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor® (omega-3-acid ethyl esters)
Description: 4 g (administered orally as 4 x 1 g capsules)
Study: NCT03610581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV16
Description: Participants will receive Ad26.HPV16 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV16
Description: Participants will receive Ad26.HPV16 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV16
Description: Participants will receive Ad26.HPV16 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV18
Description: Participants will receive Ad26.HPV18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV18
Description: Participants will receive Ad26.HPV18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV18
Description: Participants will receive Ad26.HPV18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HPV16/18
Description: Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HPV16/18
Description: Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HPV16/18
Description: Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matched placebo as a solution for intramuscular injection.
Study: NCT04688762

Intervention type: OTHER
Intervention: e-consult application (tool)
Description: A numeric application used as a support in consultation to explain the surgical management of the patient.
Study: NCT03094650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindMotion PRO
Description: Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
Study: NCT00904618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-SECUR - 'Hammock' technique
Description: The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-SECUR - 'U-Method'
Description: The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).
Description: Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
Study: NCT00591968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite Titan portable ultrasound coupled with email telediagnosis
Description: Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience.
Study: NCT02138474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacticum acidum homaccord
Description: Homeopathic remedy, made using sucrose pillules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unmedicated sucrose pillules
Study: NCT02615860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical 85% trichloroacetic acid (TCA)
Description: In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical electrocautery (ECA)
Description: In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
Study: NCT02441140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culdocentesis
Description: A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Swab
Description: . A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromopertubation
Description: Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Intravenous blood collection will be drawn from an IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
Study: NCT04083313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technique used for closing the appendiceal stump
Description: In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technique used for closing the appendiceal stump
Description: In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technique used for closing the appendiceal stump
Description: In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
Study: NCT01261130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/Alhydrogel
Description: 3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/Alhydrogel
Description: 3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel
Description: 3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel
Description: 3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel
Description: 3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel
Description: 3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/ Alhydrogel/GLA-AF
Description: 3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/ Alhydrogel/GLA-AF
Description: 3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel/GLA-AF
Description: 3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel/GLA-AF
Description: 3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel/GLA-AF
Description: 3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel/GLA-AF
Description: 3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Butang® hepatitis B vaccine
Description: 3 doses Butang® hepatitis B vaccine administered at 56 day intervals
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 500mg and Meropenem 1000mg（ IV 120min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 1000mg（ IV 120min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study: NCT01779739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineorrhaphy
Description: Procedure to build up the vaginal opening
Study: NCT01067456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiothoracic CT arm
Description: Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
Study: NCT01151644

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pandemic H1N1 influenza vaccine
Description: inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pandemic H1N1 influenza vaccine
Description: inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Study: NCT02197507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitized sensor
Description: Measure of grip strength of the dominant hand
Study: NCT04128384

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
Description: For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
Study: NCT03518073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zagotenemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zagotenemab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02890706

Intervention type: DEVICE
Group type: OTHER
Intervention: Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography
Description: Compare two techniques of the CT scanner
Study: NCT04492995

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)
Description: The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).
Description: The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases.
Study: NCT04566081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iTALKbetter: deterministic
Description: A word retrieval therapy application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iTALKbetter: reactive
Description: A word retrieval therapy application
Study: NCT01725438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample blood
Study: NCT01391767

Intervention type: DEVICE
Intervention: NuOss XC
Description: NuOss XC is a bone grafting material that will be placed in extraction socket site.
Study: NCT00951132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10mg tablets, once daily in three months
Study: NCT03785665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Capsule MD1 (Motility dummy 1)
Study: NCT02985307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Text Service
Description: A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
Study: NCT00951132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily, three months
Study: NCT04510324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red meat patties group
Description: 1. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based patties group
Description: Same as above
Study: NCT00491101

Intervention type: OTHER
Intervention: Polish Version of PAQLQ(S) by Juniper
Description: Polish Version of PAQLQ(S) by Juniper
Study: NCT03971227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuity 100 (Hexafocon A) contact lens
Description: Daily wear rigid gas permeable contact lens
Study: NCT04945499

Intervention type: DRUG
Group type: OTHER
Intervention: d-glucose
Description: using d-glucose as an contrast agent on CEST MR Imaging
Study: NCT02842333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional biological samples
Description: Blood samples
Study: NCT01603615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Study: NCT02985307

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Management Group
Description: A standard Lothian NHS group programme facilitated by a Dietitian
Study: NCT02990065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROTEIN SUPPLEMENTATION
Study: NCT01738763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
Study: NCT00491101

Intervention type: OTHER
Intervention: spirometry
Description: spirometry
Study: NCT01738763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
Study: NCT02843932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional brain MRI
Description: functional imagery during motor-perception tasks
Study: NCT01034462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Study: NCT03708029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revita Allograft
Description: Human placental allograft
Study: NCT00361907

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Pulsatile IV insulin on diabetic pt blood markers
Description: Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Effect of Pulsatile IV Insulin on blood markers
Description: Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 1000mg（ IV 120min）
Description: D1 qd;